225 related articles for article (PubMed ID: 29657587)
21. Antiarrhythmic properties of ranolazine: A review of the current evidence.
Gupta T; Khera S; Kolte D; Aronow WS; Iwai S
Int J Cardiol; 2015; 187():66-74. PubMed ID: 25828315
[TBL] [Abstract][Full Text] [Related]
22. Advanced electrophysiologic mapping systems: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(8):1-101. PubMed ID: 23074499
[TBL] [Abstract][Full Text] [Related]
23. Ranolazine for the treatment of atrial fibrillation.
Rosa GM; Dorighi U; Ferrero S; Brunacci M; Bertero G; Brunelli C
Expert Opin Investig Drugs; 2015 Jun; 24(6):825-36. PubMed ID: 25872749
[TBL] [Abstract][Full Text] [Related]
24. Sex-Related Differences in Ventricular Tachyarrhythmia Events in Patients With Implantable Cardioverter-Defibrillator and Prior Ventricular Tachyarrhythmias.
Krzowski B; Kutyifa V; Vloka M; Huang DT; Attari M; Aktas M; Shah AH; Musat D; Rosenthal L; McNitt S; Polonsky B; Schuger C; Natale A; Ziv O; Beck C; Daubert JP; Goldenberg I; Zareba W
JACC Clin Electrophysiol; 2024 Feb; 10(2):284-294. PubMed ID: 38032582
[TBL] [Abstract][Full Text] [Related]
25. Electrophysiological effects of ranolazine in a goat model of lone atrial fibrillation.
Opačić D; van Hunnik A; Zeemering S; Dhalla A; Belardinelli L; Schotten U; Verheule S
Heart Rhythm; 2021 Apr; 18(4):615-622. PubMed ID: 33232809
[TBL] [Abstract][Full Text] [Related]
26. Ranolazine for the suppression of ventricular arrhythmia: a case series.
Yeung E; Krantz MJ; Schuller JL; Dale RA; Haigney MC
Ann Noninvasive Electrocardiol; 2014 Jul; 19(4):345-50. PubMed ID: 24533675
[TBL] [Abstract][Full Text] [Related]
27. Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients.
AlTurki A; Proietti R; Russo V; Dhanjal T; Banerjee P; Essebag V
Pharmacol Res; 2019 May; 143():133-142. PubMed ID: 30914300
[TBL] [Abstract][Full Text] [Related]
28. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
Sossalla S; Maier LS
Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
[TBL] [Abstract][Full Text] [Related]
29. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
[TBL] [Abstract][Full Text] [Related]
30. A Role for Ranolazine in the Treatment of Ventricular Arrhythmias?
Andrade JG; Deyell MW
JACC Clin Electrophysiol; 2022 Jun; 8(6):763-765. PubMed ID: 35738853
[No Abstract] [Full Text] [Related]
31. Classic herbal formula Zhigancao Decoction for the treatment of premature ventricular contractions (PVCs): a systematic review of randomized controlled trials.
Liu W; Xiong X; Feng B; Yuan R; Chu F; Liu H
Complement Ther Med; 2015 Feb; 23(1):100-15. PubMed ID: 25637158
[TBL] [Abstract][Full Text] [Related]
32. Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.
Frommeyer G; Ellermann C; Dechering DG; Kochhäuser S; Bögeholz N; Güner F; Leitz P; Pott C; Eckardt L
J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1214-1219. PubMed ID: 27283775
[TBL] [Abstract][Full Text] [Related]
33. Update on ranolazine in the management of angina.
Codolosa JN; Acharjee S; Figueredo VM
Vasc Health Risk Manag; 2014; 10():353-62. PubMed ID: 25028555
[TBL] [Abstract][Full Text] [Related]
34. Role of Ranolazine in the Prevention and Treatment of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis of Randomized Clinical Trials.
Leelapatana P; Thongprayoon C; Prasitlumkum N; Vallabhajosyula S; Cheungpasitporn W; Chokesuwattanaskul R
Diseases; 2021 Apr; 9(2):. PubMed ID: 33923428
[TBL] [Abstract][Full Text] [Related]
35. Emerging clinical role of ranolazine in the management of angina.
Vadnais DS; Wenger NK
Ther Clin Risk Manag; 2010 Oct; 6():517-30. PubMed ID: 21063462
[TBL] [Abstract][Full Text] [Related]
36. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
Banon D; Filion KB; Budlovsky T; Franck C; Eisenberg MJ
Am J Cardiol; 2014 Mar; 113(6):1075-82. PubMed ID: 24462341
[TBL] [Abstract][Full Text] [Related]
37. Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.
Burashnikov A; Di Diego JM; Barajas-Martínez H; Hu D; Cordeiro JM; Moise NS; Kornreich BG; Belardinelli L; Antzelevitch C
Circ Heart Fail; 2014 Jul; 7(4):627-33. PubMed ID: 24874201
[TBL] [Abstract][Full Text] [Related]
38. COVID-19-related arrhythmias and the possible effects of ranolazine.
Chukwunyere U; Sehirli AO; Abacioglu N
Med Hypotheses; 2021 Apr; 149():110545. PubMed ID: 33636586
[TBL] [Abstract][Full Text] [Related]
39. Experimental hypothyroidism induces cardiac arrhythmias and ranolazine reverts and prevents the phenotype.
Souza DS; Marques LP; Costa AD; Cruz JS; Rhana P; Santos-Miranda A; Joviano-Santos JV; Durço AO; Vasconcelos CML; Roman-Campos D
Life Sci; 2022 Nov; 308():120945. PubMed ID: 36096245
[TBL] [Abstract][Full Text] [Related]
40. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL
Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
